Genprex Overview
- Year Founded
-
2009
- Status
-
Public
- Employees
-
25
- Stock Symbol
-
GNPX
- Share Price
-
$1.04
- (As of Friday Closing)
Genprex General Information
Description
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
Contact Information
Website
www.genprex.comCorporate Office
- 3300 Bee Cave Road
- Suite 650-227
- Austin, TX 78746
- United States
Corporate Office
- 3300 Bee Cave Road
- Suite 650-227
- Austin, TX 78746
- United States
Genprex Timeline
Genprex Stock Performance
As of 06-Dec-2024, Genprex’s stock price is $1.04. Its current market cap is $8.85M with 8.51M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.04 | $1.08 | $0.28 - $14.40 | $8.85M | 8.51M | 9.4M | -$10.69 |
Genprex Financials Summary
As of 30-Sep-2024, Genprex has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | (1,523) | 1,959 | 44,121 | 20,609 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (22,799) | (31,061) | (23,805) | (20,648) |
| Net Income | (22,710) | (30,860) | (23,741) | (20,665) |
| Total Assets | 3,907 | 10,671 | 25,085 | 42,862 |
| Total Debt | 0 | 0 | 0 | 0 |
Genprex Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Genprex Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Genprex Comparisons
Industry
Financing
Details
Genprex Competitors (51)
One of Genprex’s 51 competitors is NexImmune, a Formerly VC-backed company based in Gaithersburg, MD.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
| Monopar Therapeutics | Formerly VC-backed | Wilmette, IL | ||||
| Vertex Pharmaceuticals | Formerly VC-backed | Boston, MA | ||||
| CytImmune Sciences | Private Equity-Backed | Rockville, MD | ||||
| Sorrento Therapeutics | Formerly VC-backed | San Diego, CA |
Genprex Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Genprex Patents
Genprex Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4433498-A1 | Vectors for increasing nprl2 expression in cancer cells and methods of use thereof | Pending | 16-Nov-2021 |
Genprex Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Genprex ESG
Risk Overview
Risk Rating
Updated June, 13, 2021
41.19 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,042
Rank
Percentile
Pharmaceuticals
Industry
of 947
Rank
Percentile
Pharmaceuticals
Subindustry
of 452
Rank
Percentile
Genprex FAQs
-
When was Genprex founded?
Genprex was founded in 2009.
-
Where is Genprex headquartered?
Genprex is headquartered in Austin, TX.
-
What is the size of Genprex?
Genprex has 25 total employees.
-
What industry is Genprex in?
Genprex’s primary industry is Biotechnology.
-
Is Genprex a private or public company?
Genprex is a Public company.
-
What is Genprex’s stock symbol?
The ticker symbol for Genprex is GNPX.
-
What is the current stock price of Genprex?
As of 06-Dec-2024 the stock price of Genprex is $1.04.
-
What is the current market cap of Genprex?
The current market capitalization of Genprex is $8.85M.
-
Who are Genprex’s competitors?
NexImmune, Monopar Therapeutics, Vertex Pharmaceuticals, CytImmune Sciences, and Sorrento Therapeutics are some of the 51 competitors of Genprex.
-
What is Genprex’s annual earnings per share (EPS)?
Genprex’s EPS for 12 months was -$10.69.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
